Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance

Antibiotics (Basel). 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612.

Abstract

Due to the fact that there is a steadily increasing trend in the area of antimicrobial resistance in microorganisms, there is a need to look for new treatment alternatives. One of them is the search for new β-lactamase inhibitors and combining them with β-lactam antibiotics, with the aim of increasing the low-dose efficacy, as well as lowering the resistance potential of bacterial strains. This review presents the positive effect of meropenem in combination with a vaborbactam (MER-VAB). This latest antibiotic-inhibitor combination has found particular use in the treatment of infections with the etiology of carbapenem-resistant Enterobacterales (CRE), Gram-negative bacteria, with a high degree of resistance to available antimicrobial drugs.

Keywords: Klebsiella pneumoniae carbapenemase (KPC); carbapenem-resistant Enterobacterales (CRE); meropenem; multidrug resistance; vaborbactam; β-lactam/β-lactamase inhibitor.

Publication types

  • Review

Grants and funding

This research received no external funding.